• Silexion Therapeutics will hold an extraordinary general meeting in September 2026 at Meitar Law Offices in Ramat Gan, Israel.
• Shareholders will vote on increasing authorized share capital by 175,000,000 ordinary shares to 190,900,000 shares, par value US$ 0.135.
• A separate proposal seeks approval for a reverse share split at a ratio between 1-for-7 and 1-for-15.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-004145), on August 14, 2026, and is solely responsible for the information contained therein.